Quest Diagnostics (DGX) Receivables - Net (2009 - 2026)

Quest Diagnostics has disclosed Receivables - Net across 18 years of filings, most recently posting $1.6 billion for Q1 2026.

• Receivables - Net for Q1 2026 came in at $1.6 billion, up 13.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 13.03% YoY), and the FY2025 annual result was $1.4 billion, up 7.98% from the prior year.
• Receivables - Net came in at $1.6 billion for Q1 2026 at Quest Diagnostics, up from $1.4 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $1.6 billion in Q1 2026 to a low of $1.2 billion in Q4 2022.
• The 5-year median for Receivables - Net is $1.3 billion (2024), against an average of $1.3 billion.
• Across the five-year window, Receivables - Net decreased 16.9% in 2022 and advanced 13.03% in 2026, its largest moves.
• Quest Diagnostics' Receivables - Net stood at $1.2 billion in 2022, then increased by 1.26% to $1.2 billion in 2023, then grew by 7.77% to $1.3 billion in 2024, then gained by 7.98% to $1.4 billion in 2025, then advanced by 12.71% to $1.6 billion in 2026.
• The last three Receivables - Net figures came in at $1.6 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.